Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 746271, 9 pages
http://dx.doi.org/10.1155/2015/746271
Research Article

Immunological Hypoglycemia Associated with Insulin Antibodies Induced by Exogenous Insulin in 11 Chinese Patients with Diabetes

Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China

Received 20 January 2015; Revised 26 March 2015; Accepted 30 March 2015

Academic Editor: Mitsuhiko Noda

Copyright © 2015 Heng Quan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Harwood, “Insulin-binding antibodies and ‘spontaneous’ hypoglycemia,” The New England Journal of Medicine, vol. 262, no. 19, pp. 978–979, 1960. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Goto, O. A. Arah, M. Goto, Y. Terauchi, and M. Noda, “Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis,” British Medical Journal, vol. 347, no. 7919, Article ID f4533, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. H. C. Gerstein, M. E. Miller, R. P. Byington et al., “Effects of intensive glucose lowering in type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Duckworth, C. Abraira, and T. Moritz, “Glucose control and vascular complications in veterans with type 2 diabetes,” The New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009. View at Publisher · View at Google Scholar
  5. S. Finfer, D. R. Chittock, S. Y. Su et al., “Intensive versus conventional glucose control in critically ill patients,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1283–1297, 2009. View at Publisher · View at Google Scholar
  6. C. Jaeger, M. Eckhard, M. D. Brendel, and R. G. Bretzel, “Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy,” Experimental and Clinical Endocrinology and Diabetes, vol. 112, no. 8, pp. 416–421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Furukawa, N. Miyamura, K. Nishida, H. Motoshima, K. Taketa, and E. Araki, “Possible relevance of alpha lipoic acid contained in a health supplement in a case of insulin autoimmune syndrome,” Diabetes Research and Clinical Practice, vol. 75, no. 3, pp. 366–367, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Uchigata, Y. Hirata, and Y. Iwamoto, “Drug-induced insulin autoimmune syndrome,” Diabetes Research and Clinical Practice, vol. 83, no. 1, pp. e19–e20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. W. van Haeften, B. A. Krom, and J. E. Gerich, “Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: Effect of insulin withdrawal on insulin-antibody-binding kinetics,” Diabetes Care, vol. 10, no. 2, pp. 160–163, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. S. G. Albert and D. A. Popp, “Hypoglycemia due to serum-complexed insulin in a patient with diabetes mellitus,” Diabetes Care, vol. 7, no. 3, pp. 285–290, 1984. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Uchigata, Y. Eguchi, S. Takayama-Hasumi, and Y. Omori, “Insulin autoimmune syndrome (Hirata disease): clinical features and epidemiology in Japan,” Diabetes Research and Clinical Practice, vol. 22, no. 2-3, pp. 89–94, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Gomez Cruz, M. Jabbar, N. Saini et al., “Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male,” Pediatric Diabetes, vol. 13, no. 8, pp. 652–655, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner, “Immunological responses to exogenous insulin,” Endocrine Reviews, vol. 28, no. 6, pp. 625–652, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Wredling, P. E. Lins, and U. Adamson, “Prevalence of anti-insulin antibodies and its relation to severe hypoglycaemia in insulin-treated diabetic patients,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 50, no. 5, pp. 551–557, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. T. W. Van Haeften, “Clinical significance of insulin antibodies in insulin-treated diabetic patients,” Diabetes Care, vol. 12, no. 9, pp. 641–648, 1989. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Matsuyoshi, S. Shimoda, K. Tsuruzoe et al., “A case of slowly progressive type 1 diabetes with unstable glycemic control caused by unusual insulin antibody and successfully treated with steroid therapy,” Diabetes Research and Clinical Practice, vol. 72, no. 3, pp. 238–243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. T.-Y. Zhao, F. Li, and Z.-Y. Xiong, “Frequent reoccurrence of hypoglycemia in a type 2 diabetic patient with insulin antibodies,” Molecular Diagnosis and Therapy, vol. 14, no. 4, pp. 237–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Salardi, E. Cacciari, L. Steri et al., “An 8-year follow-up of anti-insulin antibodies in diabetic children: relation to insulin autoantibodies, HLA type, β-cell function, clinical course and type of insulin therapy,” Acta Paediatrica, vol. 84, no. 6, pp. 639–645, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Raskin, R. A. Guthrie, L. Leiter, A. Riis, and L. Jovanovic, “Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes,” Diabetes Care, vol. 23, no. 5, pp. 583–588, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. S. E. Fineberg, J. Huang, R. Brunelle, K. S. Gulliya, and J. H. Anderson Jr., “Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes,” Diabetes Care, vol. 26, no. 1, pp. 89–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Mylvaganam, J. M. Stowers, J. M. Steel, J. Wallace, J. C. MacHendry, and A. D. Wright, “Insulin immunogenicity in pregnancy: maternal and fetal studies,” Diabetologia, vol. 24, no. 1, pp. 19–25, 1983. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Weiler, M. A. Gellhaus, J. G. Carter et al., “A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery,” Journal of Allergy and Clinical Immunology, vol. 85, no. 4, pp. 713–719, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Sapin, V. Le Galudec, F. Gasser, M. Pinget, and D. Grucker, “Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro,” Clinical Chemistry, vol. 47, no. 3, pp. 602–605, 2001. View at Google Scholar · View at Scopus
  24. W. E. Owen and W. L. Roberts, “Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays,” Clinical Chemistry, vol. 50, no. 1, pp. 257–259, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Saddig, P. E. Goretzki, and A. A. R. Starke, “Differentiation of insulin secretion patterns in insulinoma,” World Journal of Surgery, vol. 32, no. 5, pp. 918–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. P. Cassidy, S. D. Luzio, M. T. Marino, and R. A. Baughman, “Quantification of human serum insulin concentrations in clinical pharmacokinetic or bioequivalence studies: what defines the ‘best method’?” Clinical Chemistry and Laboratory Medicine, vol. 50, no. 4, pp. 663–666, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Suzuki, S. Hirayama, and S. Ito, “A case of a non-insulin dependent diabetic patient with regular spontaneous hypoglycemic attacks, which were due to insulin-binding antibodies induced by human insulin therapy,” Tohoku Journal of Experimental Medicine, vol. 182, no. 2, pp. 163–173, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Ishizuka, S. Ogawa, T. Mori et al., “Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies,” Diabetes Research and Clinical Practice, vol. 84, no. 2, pp. e21–e23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Uchigata, “The novel agent, alpha lipoic acid, can cause the development of insulin autoimmune syndrome,” Internal Medicine, vol. 46, no. 17, pp. 1321–1322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. P. Morran, A. Vonberg, A. Khadra, and M. Pietropaolo, “Immunogenetics of type 1 diabetes mellitus,” Molecular Aspects of Medicine, 2015. View at Publisher · View at Google Scholar
  31. K. A. McLaughlin, K. Gulati, C. C. Richardson et al., “HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes,” The Journal of Immunology, vol. 193, no. 9, pp. 4448–4456, 2014. View at Publisher · View at Google Scholar
  32. V. Taneja, “Cytokines pre-determined by genetic factors are involved in pathogenesis of rheumatoid arthritis,” Cytokine, 2014. View at Publisher · View at Google Scholar
  33. J. U. Scher and S. B. Abramson, “Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease?” Arthritis Research and Therapy, vol. 15, no. 5, article 122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. R. Kim, L. R. Sheeler, N. Mansharamani, M. T. Haug, C. Faiman, and M. K. Gupta, “Insulin antibodies and hypoglycemia in diabetic patients: can a quantitative analysis of antibody binding predict the risk of hypoglycemia?” Endocrine, vol. 6, no. 3, pp. 285–291, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. B. M. Brooks-Worrell, D. Nielson, and J. P. Palmer, “Insulin autoantibodies and insulin antibodies have similar binding characteristics,” Proceedings of the Association of American Physicians, vol. 111, no. 1, pp. 92–96, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Oak, T.-H. T. Phan, L. K. Gilliam, I. B. Hirsch, and C. S. Hampe, “Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin,” Acta Diabetologica, vol. 47, no. 2, pp. 131–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Ionescu-Tîrgovite, I. Mincu, L. Simionescu et al., “Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 type 2 (non-insulin-dependent) diabetic patients,” Diabetologia, vol. 27, no. 6, pp. 592–595, 1984. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Fourlanos, F. Dotta, C. J. Greenbaum et al., “Latent autoimmune diabetes in adults (LADA) should be less latent,” Diabetologia, vol. 48, no. 11, pp. 2206–2212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. S. E. Fineberg, J. A. Galloway, N. S. Fineberg, M. J. Rathbun, and S. Hufferd, “Immunogenicity of recombinant DNA human insulin,” Diabetologia, vol. 25, no. 6, pp. 465–469, 1983. View at Publisher · View at Google Scholar · View at Scopus
  40. H. G. Velcovsky and K. F. Federlin, “Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA),” Diabetes Care, vol. 5, no. 2, pp. 126–128, 1982. View at Google Scholar · View at Scopus
  41. M. Iavicoli, U. Di Mario, G. A. Coronel, A. M. Dawud, P. Arduini, and M. Leonardi, “Semisynthetic human insulin: biologic and immunologic activity in newly treated diabetic subjects during a six-month follow-up,” Diabetes Care, vol. 7, no. 2, pp. 128–131, 1984. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Koyama, K. Nakanishi, M. Kato, S. Yamashita, H. Kuwahara, and H. Katori, “Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and prednisolone,” The American Journal of the Medical Sciences, vol. 329, no. 5, pp. 259–264, 2005. View at Publisher · View at Google Scholar · View at Scopus